I see patients every week who have been told for years that nothing is wrong. Their imaging is clear. Their labs are normal. Their surgeon says the implants look fine. And yet they are exhausted in a way sleep doesn't fix. They have joint pain without injury. They have cognitive changes they describe as brain fog. They have lost hair, developed rashes, experienced symptoms their primary care physician has attributed to stress, anxiety, or fibromyalgia.
They are not wrong. Something is wrong. The science now explains what.
After more than 2,000 explant procedures, published research on breast implant capsule microbiology, FDA testimony, and 15 peer-reviewed publications, here is what I can tell you about when breast augmentation goes wrong — and why conventional medicine keeps missing it.
The Implant Is Not Inert
The most pervasive misconception in breast implant surgery is that silicone implants are inert — that once placed, they simply sit there, doing nothing, generating no biological response. This has never been true.
Every implant placed in the human body triggers an immune response. The body recognizes it as a foreign object and encapsulates it in scar tissue. That capsule is normal. What happens inside the capsule is not always normal.
What the Research Now Shows
My research, published in Microorganisms (2024, 12(9):1830), examined 694 breast implant capsule specimens using polymerase chain reaction (PCR) molecular testing — the same high-sensitivity technology used to detect pathogens that standard culture testing cannot identify. The finding: 29% of capsules contained bacterial contamination. One in four. The dominant organisms were Cutibacterium acnes and Staphylococcus epidermidis — biofilm-forming bacteria that adhere to implant surfaces, develop antibiotic resistance, and persist for years without causing the acute signs of infection that medicine typically uses to diagnose a problem.
Standard culture testing on those same specimens would have been negative. No fever. No drainage. No clinical sign of infection. Just bacteria — living in the capsule, generating an immune response that the patient experiences as systemic illness.
This was not the first published evidence. Research from the Journal of Clinical Investigation (Khan et al., 2024) identified a specific molecular mechanism: S. epidermidis biofilm produces a compound from the oxidation of oleic acid that directly drives immune system activation, polarizing the immune response toward chronic inflammation. The researchers demonstrated this mechanism in tissue samples from patients with breast implant illness, in laboratory conditions, and in animal models. The correlation between bacterial abundance and immune activation was statistically striking.
This is not a theory. It is a documented biological pathway.
The Conditions That Develop
Breast Implant Illness
Breast implant illness (BII) is an umbrella term for the systemic symptoms many women develop — often years after initial augmentation — that appear to be driven by the immune response to their implants. Fatigue, brain fog, joint pain, hair loss, skin changes, and autoimmune-like symptoms are among the most commonly reported. Because these symptoms are nonspecific and because standard testing doesn't identify their source, women are frequently misdiagnosed or dismissed.
The biofilm mechanism described above provides a coherent explanation for why explant surgery resolves these symptoms for many women — and why surgery that removes the implant but leaves the capsule behind does not always provide the same resolution. The bacteria are in the capsule. If the capsule stays, the source of the immune activation may stay with it.
Capsular Contracture
When the capsule around an implant hardens and contracts, it causes visible deformity, firmness, and pain. The conventional assumption was that this was a mechanical scar response or possibly a rejection-like process. Commentary published in Plastic and Reconstructive Surgery (Kauke-Navarro & Pomahac) addressed this directly, arguing that the evidence points toward biofilm-driven chronic inflammation — the same mechanism as BII — rather than the allograft rejection model some researchers had proposed. The clinical implication: treating capsular contracture as a mechanical problem while leaving the bacteria that caused it is incomplete care.
Rupture
Implants are not permanent. Both silicone and saline implants rupture. Saline ruptures are immediately obvious — the implant deflates. Silicone gel ruptures are frequently silent, discoverable only on MRI. The FDA recommends periodic MRI monitoring for silicone gel implants specifically because ruptures can go undetected indefinitely.
When silicone ruptures, gel can migrate into the surrounding tissue and lymph nodes. The long-term systemic effects of silicone gel migration are not fully understood. Removal, when rupture is confirmed, is almost always indicated.
Why Patients Are Told Nothing Is Wrong
The diagnostic gap between what patients experience and what conventional medicine identifies has several explanations.
Standard infection culture misses biofilm-forming bacteria. Standard bloodwork does not capture the chronic low-grade immune activation that biofilm drives. Imaging that shows an intact implant with no visible capsular contracture tells the radiologist nothing about the bacterial communities living in that capsule. Medicine diagnoses what it knows to look for. If the diagnostic tools in use cannot detect the problem, the problem goes undetected.
I testified before the FDA's General and Plastic Surgery Devices Panel on exactly this problem: the gap between conventional monitoring and the actual biological picture of breast implant safety.
What Resolution Looks Like
For many women with BII-consistent symptoms, explant surgery — specifically surgery that removes both the implant and the capsule — produces meaningful improvement. In my clinical experience, patients presenting with systemic symptoms most frequently describe significant improvement in fatigue, cognitive clarity, joint pain, and other symptom domains within months of complete removal.
This is not guaranteed. Chronicity matters. The duration of immune activation affects how completely the system resets after the source is removed. But the trajectory is toward improvement for most patients who achieve complete capsule removal.
My SHARP Method — Strategic Holistic Accelerated Recovery Program — was developed in part because recovery from explant surgery is not just physical recovery from an operation. It is the beginning of a physiologic reset. Nutrition, inflammation management, and systematic support during the recovery period affect how completely patients heal. I wrote The SHARP Method and Breast Implants, Explant Surgery and Breast Implant Illness to give patients the information they need to approach that process with intention.
What to Do If You Suspect Your Implants Are the Problem
If you have symptoms you believe are related to your implants, start by documenting them. Bring that list to your consultation. Ask your surgeon whether they perform complete capsulectomy, what type of pathology testing they send capsule specimens for, and how many explant procedures they perform annually.
Ask whether they are familiar with the research on biofilm and BII. The answer to that question will tell you a great deal.
Dr. Robert Whitfield, MD is a board-certified plastic surgeon in Austin, Texas, with more than 2,000 explant procedures performed. He has published 15 peer-reviewed papers, including the largest PCR-based capsule analysis in the medical literature. He testified before the FDA on breast implant safety and is the author of Breast Implants, Explant Surgery and Breast Implant Illness and The SHARP Method.